Inceptionr LLC Boosts Stock Position in Boston Scientific Corporation $BSX

Inceptionr LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 75.7% during the third quarter, Holdings Channel.com reports. The firm owned 18,241 shares of the medical equipment provider’s stock after acquiring an additional 7,857 shares during the period. Boston Scientific accounts for about 0.4% of Inceptionr LLC’s portfolio, making the stock its 20th largest position. Inceptionr LLC’s holdings in Boston Scientific were worth $1,781,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Steph & Co. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at about $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth approximately $26,000. Finally, United Community Bank increased its stake in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.50% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BSX shares. Oppenheimer cut their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Price Performance

Shares of BSX stock opened at $71.24 on Monday. Boston Scientific Corporation has a twelve month low of $70.75 and a twelve month high of $109.50. The stock has a market capitalization of $105.71 billion, a price-to-earnings ratio of 36.72, a P/E/G ratio of 1.00 and a beta of 0.69. The stock has a fifty day simple moving average of $85.03 and a two-hundred day simple moving average of $94.47. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.